122 related articles for article (PubMed ID: 38863645)
21. The Diagnostic Utility of p16 Immunostaining in Differentiating Cancer and HSIL from LSIL and Benign in Cervical Cells.
Wu MZ; Wang S; Zheng M; Tian LX; Wu X; Guo KJ; Zhang YI; Wu GP
Cell Transplant; 2019 Feb; 28(2):195-200. PubMed ID: 30545241
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
Bergeron C; Ikenberg H; Sideri M; Denton K; Bogers J; Schmidt D; Alameda F; Keller T; Rehm S; Ridder R;
Cancer Cytopathol; 2015 Jun; 123(6):373-81. PubMed ID: 25891096
[TBL] [Abstract][Full Text] [Related]
23. p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening.
Han Q; Guo H; Geng L; Wang Y
Chin J Cancer Res; 2020 Apr; 32(2):208-217. PubMed ID: 32410798
[TBL] [Abstract][Full Text] [Related]
24. Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute.
Yang J; Nolte FS; Chajewski OS; Lindsey KG; Houser PM; Pellicier J; Wang Q; Ehsani L
Diagn Cytopathol; 2018 Jan; 46(1):22-27. PubMed ID: 29048733
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of p16
Rezhake R; Wang Y; Chen F; Hu SY; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M
Cancer Cytopathol; 2021 Sep; 129(9):679-692. PubMed ID: 33826790
[TBL] [Abstract][Full Text] [Related]
26. [Sorting role of p16(INK4a)/Ki-67 double immunostaining in the cervical cytology specimens of ASCUS and LSIL cases].
Yu J; Zhu HT; Zhao JJ; Su JZ; Xia YD
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):323-326. PubMed ID: 28468038
[No Abstract] [Full Text] [Related]
27. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing.
Zhang G; Yang B; Abdul-Karim FW
Int J Gynecol Pathol; 2015 Mar; 34(2):180-6. PubMed ID: 25675189
[TBL] [Abstract][Full Text] [Related]
28. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
29. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results.
Srodon M; Parry Dilworth H; Ronnett BM
Cancer; 2006 Feb; 108(1):32-8. PubMed ID: 16136595
[TBL] [Abstract][Full Text] [Related]
30. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
31. Performance of P16/Ki67 dual staining in triaging hr-HPV-positive population during cervical Cancer screening in the younger women.
Qian QP; Zhang X; Ding B; Jiang SW; Li ZM; Ren ML; Shen Y
Clin Chim Acta; 2018 Aug; 483():281-285. PubMed ID: 29758205
[TBL] [Abstract][Full Text] [Related]
32. [The natural history of cervical intraepithelial neoplasia I and the clinical significance of p16(INK4a) protein as a marker of progression in cervical intraepithelial neoplasia I].
Wang R; Li X; Qian M; Niu J; You Z
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):210-5. PubMed ID: 26268412
[TBL] [Abstract][Full Text] [Related]
33. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
34. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia.
Samarawardana P; Dehn DL; Singh M; Franquemont D; Thompson C; Gaido L; Torkko KC; Homer P; Burke S; Titmus MA; Nayi V; Shroyer KR
Cancer Cytopathol; 2010 Jun; 118(3):146-56. PubMed ID: 20544710
[TBL] [Abstract][Full Text] [Related]
35. Human Papillomavirus Detection and Abnormal Anal Cytology in HIV-infected Patients Using p16/Ki-67 Dual-Staining.
Patarapadungkit N; Khonhan P; Pisuttimarn P; Pientong C; Ekalaksananan T; Koonmee S
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2013-2019. PubMed ID: 32711427
[TBL] [Abstract][Full Text] [Related]
36. Immunocytochemistry of p16INK4a in liquid-based cervicovaginal specimens with modified Papanicolaou counterstaining.
Negri G; Moretto G; Menia E; Vittadello F; Kasal A; Mian C; Egarter-Vigl E
J Clin Pathol; 2006 Aug; 59(8):827-30. PubMed ID: 16467166
[TBL] [Abstract][Full Text] [Related]
37. Significance of bizarre cells in cervical screening liquid-based cytology: A prospective study of 15 cases.
Ondič O; Ferko R; Kičinová J; Bouda J; Kinkorová-Luňáčková I; Kupcová L; Zůchová M; Chytra J; Waloschek T; Tůmová Bartošková M; Alaghehbandan R; Němcová J
Cytopathology; 2018 Feb; 29(1):58-62. PubMed ID: 29154448
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL).
Frega A; Pavone M; Sesti F; Leone C; Bianchi P; Cozza G; Colombrino C; Lukic A; Marziani R; De Sanctis L; Delli Carpini G; Caserta D; Ciavattini A
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10672-10677. PubMed ID: 31858534
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia.
Saqi A; Pasha TL; McGrath CM; Yu GH; Zhang P; Gupta P
Diagn Cytopathol; 2002 Dec; 27(6):365-70. PubMed ID: 12451568
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia.
Guo M; Hu L; Baliga M; He Z; Hughson MD
Am J Clin Pathol; 2004 Dec; 122(6):894-901. PubMed ID: 15539381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
